Table 2.
Baseline characteristics of those who did or did not undergo tonsillectomy >1 yr after renal biopsy
| Baseline Characteristics | All Patients (n=800) | Baseline Data | After Propensity Score Matching | ||||
| No Tonsillectomy (n=738) | Tonsillectomy (n=62) | P Value | No Tonsillectomy (n=57) | Tonsillectomy (n=57) | P Value | ||
| Clinical findings | |||||||
| Age (yr; median and IQR) | 31.0 (25.0–42.0) | 31.0 (24.0–43.0) | 27.0 (22.8–34.3) | 0.01 | 27.0 (22.0–35.0) | 27.0 (22.0–340) | 0.80 |
| Sex (male/female) | 332/468 | 310/428 | 22/40 | 0.31 | 20/37 | 21/36 | 0.85 |
| BMI (kg/m2; median and IQR) | 21.4 (19.7–23.5) | 21.4 (19.7–23.5) | 21.1 (19.1–23.0) | 0.32 | 20.7 (18.9–22.0) | 21.1 (19.2–23.0) | 0.28 |
| SBP (mm Hg; median and IQR) | 121.0 (111.3–136.0) | 120.5 (111.0–134.0) | 117.0 (106.0–124.0) | 0.002 | 113.0 (105.5–124.5) | 116.5 (106.0–124.0) | 0.53 |
| DBP (mm Hg; median and IQR) | 76.0 (68.0–85.0) | 76.0 (67.0–84.0) | 70.0 (64.5–78.0) | 0.007 | 71.0 (62.5–80.0) | 70.0 (64.3–78.0) | 0.87 |
| MAP (mm Hg; median and IQR) | 92.0 (83.3–100.7) | 91.3 (82.7–100.5) | 85.3 (80.7–92.7) | 0.003 | 84.0 (79.3–93.0) | 85.8 (80.7–92.7) | 0.75 |
| Duration of follow-up (yr; median and IQR) | 10.0 (5.0–16.9) | 9.5 (4.0–17.0) | 12.5 (10–16.7) | 0.0006 | 14.5 (6.75–19.5) | 12.5 (10.0–16.5) | 0.68 |
| Laboratory findings | |||||||
| TP (g/dl; median and IQR) | 6.6 (6.1–7.1) | 6.7 (6.3–7.2) | 6.8 (6.3–7.2) | 0.75 | 6.6 (6.2–7.1) | 6.8 (6.3–7.3) | 0.18 |
| Cr (mg/dl; median and IQR) | 0.83 (0.69–1.08) | 0.82 (0.69–1.08) | 0.75 (0.65–0.88) | 0.004 | 0.74 (0.62–0.99) | 0.76 (0.65–0.88) | 0.65 |
| eGFR (ml/min per 1.73 m2; median and IQR) | 73.5 (56.3–91.6) | 73.7 (56.8–94.0) | 84.5 (66.5–100.3) | 0.001 | 85.6 (61.8–104.2) | 87.0 (65.9–101.0) | 0.60 |
| UA (mg/dl; median and IQR) | 5.8 (4.8–6.9) | 5.6 (4.6–6.9) | 5.3 (66.5–100.3) | 0.07 | 5.4 (4.4–6.7) | 5.3 (4.2–6.6) | 0.51 |
| T-Cho (mg/dl; median and IQR) | 192.5 (171.0–227.0) | 195.0 (170.0–226.0) | 177.0 (162.5–221.1) | 0.06 | 196.0 (169.8–228.5) | 176.5 (162.3–221.6) | 0.08 |
| TG (mg/dl; median and IQR) | 105.0 (72.0–153.0) | 105.0 (74.0–158.0) | 85.0 (60.5–121.0) | 0.02 | 109.0 (74.0–145.0) | 83.5 (59.8–120.5) | 0.07 |
| U-Prot (g/d; median and IQR) | 0.92 (0.48–1.87) | 0.76 (0.33–1.59) | 0.64 (0.30–1.10) | 0.10 | 0.70 (0.34–1.59) | 0.68 (0.3–1.07) | 0.19 |
| U-RBC (<5, 5–25, 26–49, 50–99, ≤100 counts/HPF) | 93, 305, 130, 106, 161 | 88, 282, 119, 91, 153 | 5, 23, 11, 15, 8 | 0.15 | 5, 18, 12, 8, 14 | 5, 21, 9, 15, 7 | 0.37 |
| Treatments, n | |||||||
| Immunosuppressants (−/+) | 482/318 | 470/268 | 12/50 | <0.001 | 10/47 | 11/46 | 0.81 |
| RAS inhibitors (−/+ ) | 387/413 | 368/370 | 19/43 | 0.003 | 18/39 | 19/38 | 0.84 |
BMI, body mass index; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; TP, serum total protein; Cr, serum creatinine; UA, serum uric acid; T-Cho, serum total cholesterol; TG, triglyceride; U-Prot, urinary protein excretion; U-RBC, urinary red blood cells; HPF, high-power field; RAS, renin-angiotensin system; IQR, interquartile ranges.